Assessment of inhibitor risk after switching from plasma-derived factor VIII concentrate to recombinant factor VIII (Brasil-RFVIII: brazilian study of inhibitor linked to recombinant factor VIII)

被引：0
作者：
Prezotti, A. [1 ,2 ]
Montalvao, S. [1 ]
Marques, A. [3 ]
Ferreira, C. [4 ]
Oliveira, L. [5 ]
Villaca, P. [6 ]
Ferreira Filho, L. [7 ]
Lorenzato, C. [8 ]
Medina, S. [1 ]
Araujo, F. [9 ]
Ozelo, M. [1 ]
机构：
[1] Univ Campinas UNICAMP, INCT SANGUE HEMOCTR UNICAMP, Campinas, SP, Brazil
[2] Hemoctr Espirito Santo, Hematol, Vitoria, Brazil
[3] HEMORIO, Hematol, Rio De Janeiro, Brazil
[4] Hemoctr Rio Grande do Sul HEMORS, Hematol, Porto Alegre, RS, Brazil
[5] Univ Sao Paulo USP Ribeirao Preto, Hemoctr Ribeirao Preto, Ribeirao Preto, Brazil
[6] HCFMUSP Univ Sao Paulo, Hematol, Sao Paulo, Brazil
[7] HEMOCTR CEARA HEMOCE, Hematol, Fortaleza, Ceara, Brazil
[8] HEMOCTR PARANA HEMEPAR, Hematol, Curitiba, Parana, Brazil
[9] Hemoctr Pernambuco HEMOPE, Hematol, Recife, PE, Brazil
来源：
JOURNAL OF THROMBOSIS AND HAEMOSTASIS | 2015年 / 13卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PO286-MON
引用
收藏
页码：366 / 366
页数：1
相关论文
共 50 条
[41]   Effect of factor VIII concentrate on leucocyte cytokine production: characterization of TGF-beta as an immunomodulatory component in plasma-derived factor VIII concentrate [J].
Hodge, G ;
Flower, R ;
Han, P .
BRITISH JOURNAL OF HAEMATOLOGY, 1999, 106 (03) :784-791
[42]   Factor VIII Inhibitor Bypass Activity and Recombinant Activated Factor VII in Cardiac Surgery [J].
Rao, Vidya K. ;
Lobato, Robert L. ;
Bartlett, Blake ;
Klanjac, Mark ;
Mora-Mangano, Christina T. ;
Soran, P. David ;
Oakes, Daryl A. ;
Hill, Charles C. ;
van der Starre, Pieter J. .
JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA, 2014, 28 (05) :1221-1226
[43]   Factor-VIII-inhibitor-bypassing-fraction/Recombinant-factor-VIIaLack of efficacy [J].
Reactions Weekly, 2024, 2004 (1) :208-208
[44]   CONTROL OF HEMOSTASIS WITH RECOMBINANT FACTOR-VIIA IN PATIENT WITH INHIBITOR TO FACTOR-VIII [J].
INGERSLEV, J ;
FELDSTEDT, M ;
SINDETPEDERSEN, S .
LANCET, 1991, 338 (8770) :831-832
[45]   Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review [J].
Iorio, A. ;
Halimeh, S. ;
Holzhauer, S. ;
Goldenberg, N. ;
Marchesini, E. ;
Marcucci, M. ;
Young, G. ;
Bidlingmaier, C. ;
Brandao, L. R. ;
Ettingshausen, C. E. ;
Gringeri, A. ;
Kenet, G. ;
Knoefler, R. ;
Kreuz, W. ;
Kurnik, K. ;
Manner, D. ;
Santagostino, E. ;
Mannucci, P. M. ;
Nowak-Goettl, U. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2010, 8 (06) :1256-1265
[46]   DETERMINATION OF ANTI-FACTOR-VIII ANTIBODIES RESPONSIBLE FOR THE INHIBITOR TITTER IN HEMOPHILIACS TREATED WITH PLASMA OR RECOMBINANT FACTOR-VIII AND IN SPONTANEOUS INHIBITORS [J].
SCANDELLA, D ;
NAKAI, H ;
FELCH, M ;
PRESCOTT, R ;
BRAY, G ;
HURST, D .
BLOOD, 1994, 84 (10) :A240-A240
[47]   Cost analysis of plasma-derived factor VIII/von Willebrand factor versus recombinant factor VIII for treatment of previously untreated patients with severe hemophilia A in the United States [J].
Neufeld, Ellis J. ;
Sidonio, Robert F., Jr. ;
O'Day, Ken ;
Runken, M. Chris ;
Meyer, Kellie ;
Spears, Jeffrey .
JOURNAL OF MEDICAL ECONOMICS, 2018, 21 (08) :762-769
[48]   Effect of recombinant and plasma-derived von Willebrand Factor on the procoagulant activity of factor VIII in thrombin generation assays [J].
Knappe, Sabine ;
Till, Susanne ;
Scheiflinger, Friedrich ;
Dockal, Michael .
HAEMOPHILIA, 2014, 20 :28-28
[49]   ECONOMIC IMPACT OF TREATING SEVERE HEMOPHILIA A PATIENTS WITH PLASMA-DERIVED FACTOR-VIII/VWF VERSUS RECOMBINANT FACTOR-VIII IN THE UNITED STATES [J].
O'Day, K. ;
Runken, M. C. ;
Meyer, K. L. ;
Spears, J. B. .
VALUE IN HEALTH, 2017, 20 (05) :A216-A217
[50]   COPPER-ATOM IDENTIFICATION IN THE DIFFERENT ACTIVE AND INACTIVE FORMS OF RECOMBINANT FACTOR-VIII-DELTA-II AND PLASMA-DERIVED FACTOR-VIII [J].
BIHOREAU, N ;
RAMON, C ;
PIN, S ;
FONTAINEAUPART, MP .
THROMBOSIS AND HAEMOSTASIS, 1995, 73 (06) :1215-1215
12345